Across TCGA pan-cancer cohorts, SFMBT2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SFMBT2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SFMBT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SFMBT2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC and GBM are the cancer types where SFMBT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	1.000	0.705	.001	34	view →
GBM	DFS	Median	All	0.829	0.485	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SFMBT2 tumor-vs-normal RNA expression · all SFMBT2 data types